Squamous cell carcinoma is the lung cancer subtype most strongly linked to hypercalcemia. In one study of lung cancer patients with elevated calcium levels, squamous cell carcinoma accounted for roughly two-thirds of all cases. While other types of lung cancer can raise calcium too, squamous cell carcinoma does so far more often and through a distinct biological mechanism.
Why Squamous Cell Carcinoma Leads the List
About 20% of all lung cancer patients develop hypercalcemia at some point during their disease. When researchers broke that number down by cancer subtype, squamous cell carcinoma made up 66.7% of the cases, followed by adenocarcinoma at 16.7%. Other subtypes were responsible for the remaining fraction. This makes squamous cell lung cancer one of the most common causes of cancer-related high calcium overall, not just among lung cancers.
The reason comes down to a protein the tumor produces called PTHrP (parathyroid hormone-related protein). PTHrP closely resembles the hormone your parathyroid glands normally use to regulate calcium. It binds to the same receptor, which tricks the body into behaving as though calcium levels are too low. Two things happen: your kidneys hold onto calcium instead of filtering it out, and cells called osteoclasts ramp up bone breakdown, releasing stored calcium into the bloodstream. The result is calcium levels that climb well above normal, sometimes dangerously so. This process is called “humoral hypercalcemia of malignancy” because the tumor doesn’t need to be anywhere near the bones to cause it. It works through a substance circulating in the blood.
Other Lung Cancer Types That Raise Calcium
Adenocarcinoma, the most common type of lung cancer overall, can also cause hypercalcemia, though it does so less frequently than squamous cell carcinoma. In some cases, adenocarcinoma produces PTHrP through the same humoral mechanism. Rarely, it may also co-secrete both PTHrP and an active form of vitamin D, creating a double pathway for calcium elevation.
Small cell lung cancer (SCLC) is considered an uncommon cause of hypercalcemia. When it does occur, the mechanism is poorly understood. One theory is that SCLC cells infiltrating bone marrow trigger local production of inflammatory signals that activate osteoclasts, breaking down bone and releasing calcium. Certain variant forms of SCLC can also produce active vitamin D, though this has been documented in only a handful of case reports worldwide.
Bone Metastases as a Separate Pathway
Any type of lung cancer that spreads to bone can cause hypercalcemia through a completely different route. When cancer cells settle in bone, they don’t dissolve it directly. Instead, they release signaling molecules (interleukins, prostaglandins, and growth factors) that stimulate osteoclasts to break down the surrounding bone tissue. This destruction frees large amounts of calcium into the bloodstream. High osteoclast activity also fuels further tumor growth in bone, creating a cycle where metastatic growth and bone destruction reinforce each other.
This “osteolytic” mechanism can operate alongside the humoral PTHrP pathway. A patient with squamous cell carcinoma that has also metastasized to bone may have both mechanisms driving their calcium levels up simultaneously.
How Hypercalcemia Feels
Symptoms depend on how high calcium climbs and how quickly it gets there. Cancer-related hypercalcemia tends to develop more acutely than other causes, which often makes symptoms feel more severe even at the same calcium level.
- Mild (10.5 to 11.9 mg/dL): Loss of appetite, constipation, and general fatigue are typical. These are easy to dismiss as side effects of cancer treatment.
- Moderate (12.0 to 13.9 mg/dL): Nausea, vomiting, increased thirst and urination, muscle weakness, anxiety, depression, and difficulty concentrating. Kidney function often starts to decline because the kidneys are working to excrete excess calcium while simultaneously losing fluid.
- Severe (above 14 mg/dL): Confusion, extreme lethargy, stupor, seizures, and dangerous heart rhythm changes. This is a medical emergency that can progress to coma or cardiac arrest.
Bone pain, itching, and generalized abdominal pain are also reported. Because many of these symptoms overlap with advanced cancer itself, hypercalcemia is sometimes missed initially, particularly when it develops gradually.
How It’s Treated
The immediate priority is bringing calcium levels down. For moderate to severe cases, the standard approach involves intravenous fluids to rehydrate and help the kidneys flush calcium, paired with a bone-protective medication that slows osteoclast activity. The Endocrine Society recommends either an IV bisphosphonate or denosumab, with a slight preference for denosumab. When calcium exceeds 14 mg/dL, a hormone called calcitonin is typically added for the first 48 to 72 hours because it lowers calcium faster than the other medications, though its effect wears off quickly.
These treatments address the calcium emergency but not the underlying cancer. Long-term control of hypercalcemia depends on treating the tumor itself. If the cancer responds to chemotherapy, immunotherapy, or radiation, calcium levels often stabilize.
What Hypercalcemia Means for Prognosis
Developing hypercalcemia in the setting of lung cancer is a serious prognostic sign. Across multiple studies, median survival after a diagnosis of cancer-related hypercalcemia ranges from roughly one to three months, with one large study reporting a median of 52 days. These numbers reflect a population with advanced disease, since hypercalcemia most commonly appears in later stages. It signals that the cancer is producing systemic effects beyond the primary tumor site, whether through widespread PTHrP secretion or extensive bone involvement. Approximately 25 to 30% of all cancer patients develop hypercalcemia at some point, and its appearance generally marks a shift toward more aggressive disease management and supportive care.